Clinical Trials Logo
  1. Home
  2. Spinocerebellar Ataxia Type 2
  3. NCT03347344

Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL) — ATRIL  

Spinocerebellar Ataxia Type 2 Clinical Trial

Official title:
Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2

Clinical Trial Summary

ATRIL is a multi-centric, double-blind randomized, two-arm controlled study. 42 SpinoCerebellar Ataxia type 2 (SCA2) patients, both gender, at least 18 years of age will be included. Riluzole 50 mg will be administered (per os) twice a day, versus one group with placebo for 12 months. Riluzole (Rilutek®) is a benzothiazole drug, market approved, for Amyotrophic Lateral Sclerosis (ALS). It delays the onset of ventilator-dependence or tracheostomy in selected patients and may increase survival. Scale for the Assessment and Rating of Ataxia (SARA) will be used at M0, M6 and M12. To assess primary criterion, the percentage of patients with a decrease of at least 1 point of the SARA score between the inclusion visit, and Visit 3 (Months 12) will be calculated.

Clinical Trial Description

Inherited cerebellar ataxias are genetically heterogeneous neurological disorders. They are characterized by ataxic gait and cerebellar dysarthria that progresses over time with loss of ambulation and speech. The mutations by expansions of CAG triplets in the genes ATXN1 (SCA1), ATXN 2 (SCA2), 3 (SCA3), CACNA1A (SCA6), ATXN 7 (SCA7), and TBP (SCA17) are responsible for 50% of hereditary forms There is no curative or preventive treatment. This phase III study is a multi-centric, double-blind randomized, two-arm controlled study (one group with 50 mg Riluzole twice a day versus one group with placebo), to measure the efficacy of treatment with riluzole in SCA2 patients during 12 months. Amelioration is defined by a 1 point decrease of the SARA score. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03347344
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase Phase 3
Start date January 17, 2018
Completion date December 14, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT01470729 - Biomarkers in Autosomal Dominant Cerebellar Ataxia
Completed NCT04288128 - Integrated Functional Evaluation of the Cerebellum
Active, not recruiting NCT03701399 - Troriluzole in Adult Subjects With Spinocerebellar Ataxia Phase 3
Withdrawn NCT04301284 - Study of CAD-1883 for Spinocerebellar Ataxia Phase 2
Active, not recruiting NCT04268147 - Instrumented Data Exchange for Ataxia Study
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Active, not recruiting NCT05826171 - Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia N/A
Completed NCT03120013 - Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia N/A
Not yet recruiting NCT03378414 - Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia Phase 2
Active, not recruiting NCT03408080 - Open Pilot Trial of BHV-4157 Phase 3
Completed NCT04153110 - Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia N/A
Recruiting NCT01060371 - Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias